PH1002
Research-stage proposed biosimilar candidate referencing ocrelizumab
Development code
PH1002
Reference molecule
Ocrelizumab
Molecular target
CD20
Therapeutic area
Neurology
Scientific Profile
PH1002 is a research-stage proposed biosimilar candidate referencing ocrelizumab. The intended molecule is a recombinant humanized, glycosylated IgG1 monoclonal antibody directed against CD20-expressing B lymphocytes. Planned development activities include mammalian-cell culture process development and stepwise comparative analytical and functional studies. Biosimilarity has not been established.
Development Focus
The program is focused on comparative assessment of primary and higher-order structure, glycan and charge profiles, purity, aggregates, stability, CD20 binding, Fcγ-receptor and C1q interactions, antibody-dependent cellular cytolysis, and complement-dependent cytotoxicity. Phagocytosis- and apoptosis-related assays may be included where scientifically justified. The reference-product context includes relapsing and primary progressive forms of multiple sclerosis, although authorized populations differ by jurisdiction. PH1002 currently has no established indication.
Proposed Mode of Action
PH1002 is designed to bind CD20 on pre-B and mature B lymphocytes, including memory B-cell populations. CD20 is generally absent from lymphoid stem and pro-B cells and from plasmablasts and plasma cells. Surface binding is intended to trigger antibody-dependent cellular cytolysis and complement-mediated lysis, thereby reducing CD20-positive B cells. The precise mechanism through which this biology produces therapeutic effects in multiple sclerosis is not fully elucidated, and no clinical effect has been established for PH1002.
- PH1002 is a research-stage proposed biosimilar candidate. Biosimilarity, safety, efficacy, approved indications, and interchangeability, where such a designation exists, have not been established for PH1002, and PH1002 has not been approved by any regulatory authority. References to the reference medicine, its mechanism of action, and its authorized indications are provided solely for scientific context and do not imply the same characteristics, clinical profile, or regulatory status for PH1002.
Get in touch